Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant
J Dtsch Dermatol Ges. 2010 Apr;8(4):272-4.
doi: 10.1111/j.1610-0387.2009.07215.x.
Epub 2009 Sep 16.
[Article in
English,
German]
Affiliation
- 1 Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Germany.
Abstract
The bradykinin B2 receptor antagonist icatibant has recently become available for treating hereditary angioedema. Our observations demonstrate icatibant to be effective and safe for the treatment of both, abdominal and cutaneous attacks in a practice setting beyond clinical studies.
MeSH terms
-
Adult
-
Angioedemas, Hereditary / drug therapy*
-
Angioedemas, Hereditary / pathology*
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Bradykinin / administration & dosage
-
Bradykinin / analogs & derivatives*
-
Bradykinin Receptor Antagonists*
-
Female
-
Humans
-
Male
-
Middle Aged
-
Treatment Outcome
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Bradykinin Receptor Antagonists
-
icatibant
-
Bradykinin